Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orkambi in children 6-11 with CF (F508del homozygous)
NCT02514473Phase 3Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- Jul 2015
- Primary completion
- Sep 2016
- Modality
- Small Molecules
- Countries
- 9
01
Overview
A Phase 3 trial of lumacaftor, ivacaftor in cystic fibrosis (CF), sponsored by Vertex Pharmaceuticals. Started Jul 2015; status: completed.
02
Drugs
lumacaftorivacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT02514473.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02514473.